We identified receptor tyrosine kinases (RTKs), such as anaplastic lymphoma kinase (ALK), as druggable neuroblastoma cell survival activators that can be targeted by treatment with small molecule inhibitors, thus sensitizing neuroblastomas to HDAC8 inhibition. This evidence concerns the gene ALK and neuroblastoma.